NeuroBo Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: MTVA · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
TL;DR
NeuroBo Pharma calling for a shareholder vote - big changes might be coming.
AI Summary
On September 18, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does not specify the exact nature of the vote or the proposals to be presented to the shareholders.
Why It Matters
This filing indicates that NeuroBo Pharmaceuticals is preparing to hold a shareholder vote, which could lead to significant corporate actions or changes in governance.
Risk Assessment
Risk Level: medium — The filing signals potential corporate actions that could impact the company's future, but lacks specific details on the proposals.
Key Numbers
- 001-37809 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-2389984 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- September 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138 (address) — Principal executive offices
FAQ
What specific matters will be submitted for a vote by NeuroBo Pharmaceuticals' security holders?
The filing does not specify the exact matters to be submitted for a vote, only that such a submission is occurring.
When is the shareholder vote expected to take place?
The filing does not provide a date for the shareholder vote, only the date of the report (September 18, 2024).
Has NeuroBo Pharmaceuticals provided any details about the proposals to be voted on?
No, the 8-K filing does not include details regarding the specific proposals for the shareholder vote.
What is the significance of filing an 8-K for 'Submission of Matters to a Vote of Security Holders'?
This type of filing is required when a company is submitting significant matters, such as mergers, acquisitions, or changes to corporate governance, for approval by its shareholders.
Does this filing indicate any recent corporate actions or changes at NeuroBo Pharmaceuticals?
The filing indicates that the company is preparing for a shareholder vote, which often precedes significant corporate actions or changes, but the specific actions are not detailed in this report.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2024-09-19 16:10:30
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240918x8k.htm (8-K) — 53KB
- nrbo-20240918x8k001.jpg (GRAPHIC) — 12KB
- 0001558370-24-012900.txt ( ) — 204KB
- nrbo-20240918.xsd (EX-101.SCH) — 3KB
- nrbo-20240918_lab.xml (EX-101.LAB) — 16KB
- nrbo-20240918_pre.xml (EX-101.PRE) — 10KB
- nrbo-20240918x8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 18, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) held a virtual special meeting of stockholders (the "Special Meeting" ). The Company's stockholders voted on two proposals at the Special Meeting as set forth below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 21, 2024. There were 3,113,652 shares of common stock, par value $0.001 per share (the "Common Stock" ) present and entitled to vote at the Special Meeting, online or by proxy, which constituted a quorum for the transaction of business. In deciding the proposals at the Special Meeting, each share of Common Stock represented one vote. At the Special Meeting, the Company's stockholders voted on the following proposals: 1. To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock, in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of: (i) up to 5,089,060 shares of Common Stock issuable upon the exercise of Series A Common Stock Purchase Warrants issued in a private placement pursuant to those certain Securities Purchase Agreements, dated as of June 23, 2024, entered into by and among the Company and certain institutional investors named therein (the "Securities Purchase Agreements" ); (ii) up to 7,633,591 shares of Common Stock issuable upon the exercise of Series B Common Stock Purchase Warrants issued in a private placement pursuant to the Securities Purchase Agreements; and (iii) up to 127,227 shares of Common Stock issuable upon the exercise of Placement Agent Common Stock Purchase Warrants issued in a private placement pursuant to that certain Engagement Letter, dated as of May 23, 2024, as amended, by and between the Company and H.C. Wainwright & Co., LLC (the "Issuance Proposal" ); and 2. To authorize one or more adjournments
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: September 19, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer